Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions.

British journal of cancer - 20 Aug 2013

Moon D H, Lee J-M, Noonan A M, Annunziata C M, Minasian L, Houston N, Hays J L, Kohn E C

Abstract excerpt

BACKGROUND: We tested the hypothesis that BRCA1/2 mutation carriers with ovarian cancer are at higher risk of carboplatin hypersensitivity reactions (HSRs). METHODS: Medical records of women enrolled in two carboplatin+olaparib clinical trials (NCT01237067/NCT01445418) were reviewed. A maximum of eight cycles containing carboplatin were administered. RESULTS: All women (N=87) had good performance status and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carboplatin
Share to Carcinoma
Share to Drug Hypersensitivity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Multivariate Analysis

Share to Phthalazines

Share to Piperazines

Source

Open in PubMed Open full text

Identifiers

PMID: 23867999
DOI: 10.1038/bjc.2013.389
PMCID: PMC3749564

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions.PMID 23867999Read ↗

Clinical characteristics and genetic HLA marker for patients with oxaliplatin-induced adverse drug reactions.Semantic proximity Read ↗

Exploring the effect of BRCA1/2 status on chemotherapy-induced hematologic toxicity in patients with ovarian cancer.Semantic proximity Read ↗

Differential presentation of hypersensitivity reactions to carboplatin and oxaliplatin: phenotypes, endotypes and management with desensitization.Semantic proximity Read ↗

Management of Hypersensitivity in Oncology Practice: Risk Stratification, Phenotypic Markers, and Desensitization ProtocolsSemantic proximity Read ↗

Carboplatin/taxane-induced gastrointestinal toxicity: a pharmacogenomics study on the SCOTROC1 trial.Semantic proximity Read ↗

Chemotherapy Toxicity in BRCA Mutation Carriers Undergoing First-Line Platinum-Based ChemotherapySemantic proximity Read ↗

Differential presentation of hypersensitivity reactions to carboplatin and oxaliplatin: Phenotypes, endotypes, and management with desensitization.Semantic proximity Read ↗

Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trial.Semantic proximity Read ↗

A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.Semantic proximity Read ↗

A genome-wide association study of chemotherapy-induced alopecia in breast cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.